CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE |
|
<
|
Référence |
mg/m² CDDP VP16 VDS VBL
VNR |
n |
(stIV) |
%RO |
p |
SM |
p |
|
Dhingra,
1985
(1) |
I.
120 - + - - II. 60-80 + - - - III. 50-80 + + - - |
62 67 62 |
(54) (57) (52) |
35 30 22 |
NS |
29 s. 29 s. 28 s. |
NS |
|
Kris, 1985
(2) |
I. 120 - + - - II. 120 - - + - |
48 49 |
(43) (41) |
33 41 |
NS |
8,5 m. 12,3 m. |
NS |
|
Ruckdeschel,
1986
(3) |
I. 120 - + - - II. 120 + - - - |
126 124 |
(126) (124) |
25 20 |
NS |
26,0 s. 26,6 s. |
NS |
|
Paccagnella,
1986
(4) |
I. 100 - + - - II. 100 + - - - |
35 38 |
(5) (7) |
48 36 |
NS |
43 s. 47 s. |
NS |
|
Hainsworth,
1989
(5) |
I. 60 - + - - II. 60 + - - - III. 60 + + - - |
52 49 51 |
(36) (40) (42) |
10 6 24 |
S |
24,5 s. 16,5 s. 20 s. |
0,08 |
|
Niiranen,
1990
(6) |
I. 90 - + - - II. 90 + - - - |
72 64 |
(?) (?) |
35 16 |
0,06 |
181 j. 166
j. |
NS |
|
Weick,
1991
(7) |
I. 100 + - - - II. 100 - - + - |
135 142 |
(135) (142) |
16 24 |
S |
5,3
m. 5,9
m. |
NS |
|
Le
Chevalier, 1994
(8) |
I.
120 - - - + II. 120 - + - - |
206 200 |
(102) (109) |
30 19 |
0,02 |
40
s. 32
s. |
0,08 |
|
Crino,
1995
(9) |
I. 120 + - - - |
130 |
(76) |
23 |
0,01 |
27
s. |
0,04 |
|
Kosmidis,
1996
(10) |
I. 100 -
- +
- II. 100
+
- -
- |
106 106 |
(70) (62) |
29 25 |
NS |
8,5
m 9,4
m |
NS |
|
Pérol, 1996
(11) |
I.
120 - - - + II. 120 - + - - |
114 113 |
|
25 17 |
NS |
35
s 33
s |
NS |
|
Jeremic, 1999
(12) |
I. Carbo po - - - II. Carbo iv - - - |
84 84 |
tous |
23 19 |
NS |
8
m 7
m |
NS |
|
Jassem, 2001
(13) |
I. - - - - po II. - - - - iv |
77 38 |
|
14 12 |
|
9,3
m 7,9
m |
|
|
Tan, 2009
(14) I |
I.
Cisplatine (80) + vinorelbine iv/peros |
190 |
80
% |
27 |
NS |
|
NS |
|
II.
Cisplatine (75) + docétaxel |
191 |
85
% |
27 |
|
Références
(1) Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1985; 3(2):176-183.
(2) Kris MG, Gralla RJ, Kalman LA, Kelsen DP, Casper ES, Burke MT et al. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985; 69(4):387-395.
(3) Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA et al. A randomized trial of the four most active regimens for metastatic non- small-cell lung cancer. J Clin Oncol 1986; 4(1):14-22.
(4) Paccagnella A, Brandes A, Pappagallo GL, Simioni G, Fosser VP, Vinante O et al. Cisplatin plus vindesine versus cisplatin plus VP16 versus doxorubicin plus cytoxan in non-small-cell carcinoma of the lung. A randomized study. Tumori 1986; 72(4):417-425.
(5) Hainsworth JD, Johnson DH, Hande KR, Greco FA. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens. Am J Clin Oncol 1989; 12(4):345-349.
(6) Niiranen A, Niitamo-Korhonen S, Holsti P., Holsti LR. A randomized comparison of cisplatin-vindesine and cisplatin-etoposide for the treatment of previously untreated, advanced non-small cell lung cancer. Cancer Journal 1990; 3:219-223.
(7) Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CAJ et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991; 9(7):1157-1162.
(8) Le Chevalier T, Pujol JL, Douillard JY, Alberola V, Monnier A, Riviere A et al. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non- small cell lung cancer: an expanded analysis. Semin Oncol 1994; 21(5 Suppl 10):28-33.
(9) Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E et al. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 1995; 6(4):347-353.
(10) Kosmidis P, Mylonakis N, Fountzilas G, Pavlidis N, Samantas E, Karabelis A et al. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group. Ann Oncol 1996; 7(5):517-520.
(11) Perol M, Guerin JC, Thomas P, Poirier R, Carles P, Robinet G et al. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Francais de Pneumo-Cancerologie'. Lung Cancer 1996; 14(1):119-134.
(12) Jeremic B, Shibamoto Y, Milicic B, Milisavljevic S, Nikolic N, Dagovic A et al. Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial. Lung Cancer 1999; 25(3):207-214.
(13) Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12(10):1375-1381.
(14) Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009 Jul;20(7):1249-56.